Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty

Pediatric Endocrinology Reviews

Volumn 11, Issue 3, 2014, Pages 306-317

  Thornton, Paul ^a   Silverman, Lawrence A ^b   Geffner, Mitchell E ^c   Neely, E Kirk ^d   Gould, Errol ^e   Danoff, Theodore M ^e,f  

^a Cook Children's Medical Center ^*  (United States)

^b Atlantic Health   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d STANFORD UNIVERSITY   (United States)

^e ENDO PHARMACEUTICALS INC   (United States)

^f Clarus Therapeutics Inc   (United States)

Author keywords

Fertility; Gonadotropin dependent; Gonadotropin releasing hormone agonist; Menarche; Polycystic ovary syndrome; Precocious puberty; Reproductive function

Indexed keywords

BUSERELIN; DESLORELIN; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; NAFARELIN; TRIPTORELIN; GONADORELIN;

ARTICLE; BODY MASS; BONE DENSITY; CLINICAL OUTCOME; DRUG EFFECT; DRUG INDICATION; DRUG UTILIZATION; FEMALE FERTILITY; FERTILITY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PROGENY; REPRODUCTION; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADOLESCENT; BODY COMPOSITION; CHILD; DRUG POTENTIATION; FEMALE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; MENARCHE; OVARY; OVULATION; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MENARCHE; MENSTRUAL CYCLE; OVARY; OVULATION; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS; TREATMENT OUTCOME;

EID: 84899564175     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Biro FM, Galvez MP, Greenspan LC, Succop PA, Vangeepuram N, Pinney SM, Teitelbaum S, Windham GC, Kushi LH, Wolff MS. Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. Pediatrics 2010; 126:e583-590
2. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, Hasemeier CM. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505-512
3. McDowell MA, Brody DJ, Hughes JP. Has age at menarche changed? Results from the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Adolesc Health 2007; 40:227-231
4. Herman-Giddens ME. Recent data on pubertal milestones in United States children: the secular trend toward earlier development. Int J Androl 2006; 29:241-246; discussion 286-290
5. Kaplowitz PB, Oberfield SE. Reexamination of the age timit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936-941
6. Sorensen K, Mouritsen A, Aksglaede L, Hagen CP, Mogensen SS, Juul A. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012; 77:137-145
7. Cesario SK, Hughes LA. Precocious puberty: a comprehensive review of literature. J Obstet Gynecol Neonatal Nurs 2007; 36:263-274
8. Partsch CJ, Sippell WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update 2001; 7:292-302
9. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358:2366-2377
10. Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 2005; 116:1323-1328
11. Soriano-Guillen L, Corripio R, Labarta JI, Canete R, Castro-Feijoo L, Espino R, Argente J. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab 2010; 95:4305-4313
12. Teilmann G, Pedersen CB, Skakkebaek NE, Jensen TK. Increased risk of precocious puberty in internationally adopted children in Denmark. Pediatrics 2006; 118:e391-399
13. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84:4583-4590
14. Mul D, Hughes IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008; 159 (suppl 1):S3-8
15. Crowley WF, Jr., Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB, Jr. Therapeutic use of pituitary desensitization with a long-acting Ihrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52:370-372
16. Laron Z, Kauli R, Zeev ZB, Comaru-Schalty AM, Schally AV. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty. Lancet 1981; 2:955-956
17. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Group E-LGACC, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M, Wit JM. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752-762
18. Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 2002; 16:165-189
19. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Flood L, Gray W, Tierney D. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92:1697-1704
20. Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012; 97:1572-1580
21. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91:1862-1867
22. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011; 159:982-987
23. Mericq V, Lammoglia JJ, Unanue N, Villaroel C, Hernandez MI, Avila A, Iniguez G, Klein KO. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol (Oxf) 2009; 71:686-690
24. Lewis KA, Goldyn AK, West KW, Eugster EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013; 163:1214-1216
25. Rahhal S, Clarke WL, Kletter GB, Lee PA, Neely EK, Reiter EO, Saenger P, Shulman D, Silverman L, Eugster EA. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009; 2009:812517
26. Silverman LA, Kletter GB, Neely EK, Eugster EA, Chitra S, Owens G. Once-yearly histrelin subdermat implants provide continuous suppression of the hypothalamic-pituitary-gonadal axis for up to 6 years in children with central precocious puberty. 2013 Pediatric Academic Societies Annual Meeting; May 5, 2013; Washington, D.C.
27. Silverman LA, Kletter GB, Neely EK, Potts S, Danoff TM, Goutd E. Treatment of children with central precocious puberty: 3 years of continuous suppression with histrelin subdermal implants. Pediatric Endocrinology Nursing Society 2012; 27:e9-e10
28. Silverman LA, Kletter GB, Neely EK, Potts S, Gould E, Terleckyj O, Danoff TM. Histrelin subdermal implants provide continuous suppression of the hypothalamic-pituitary-gonadal axis for 4 years in children with central precocious puberty. Endocrine Society's 94th Annual Meeting and Expo; June 24, 2012; Houston, Texas
29. Hirsch HJ, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T, Gelber H, Spitz IM. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005; 116:e798-802
30. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB, Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999; 84:44-49
31. Chiavaroli V, Liberati M, D'Antonio F, Masuccio F, Capanna R, Verrotti A, Chiarelli F, Mohn A. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010; 163:55-62
32. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, lughetti L, Pasquino AM, Salerno MC, Marseglia L, Crisafulli G. Menstrual cycle pattern during the first gynaecological years in girls with precocious puberty following gonadotropin-releasing hormone analogue treatment. Eur J Pediatr 2007; 166:73-74
33. Cassio A, Bal MO, Orsini LF, Balsamo A, Sansavini S, Gennari M, De Cristofaro E, Cicognani A. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr 2006; 149:532-536
34. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999; 81:329-332
35. Heger S, Muller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, Sippell WG. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006; 254255:217-220
36. Jay N, Mansfield MJ, Blizzard RM, Crowley WF, Jr., Schoenfeld D, Rhubin L, Boepple PA. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992; 75:890-894
37. Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-Goldberg C, Chwalisz K. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010; 2010:398639
38. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93:190-195
39. Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011; 27:524-528
40. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004; 61:626-634
41. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, Bougneres PF. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 1999; 84:3575-3578
42. Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 1993; 147:653-657
43. Kauli R, Kornreich L, Laron Z. Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy. Horm Res 1990; 33:11-17
44. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwe C, Jansen M, Gerver WJ, Waelkens J, Drop S. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996; 75:292-297
45. Schroor EJ, Van Weissenbruch MM, Delemarre-van de Waal HA. Long-term GnRH-agonist treatment does not postpone central development of the GnRH pulse generator in girls with idiopathic precocious puberty. J Clin Endocrinol Metab 1995; 80:1696-1701
46. Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013; 163:532-536
47. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, Satoh M, Kugu K. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005; 90:1371-1376
48. Alessandri SB, Pereira Fde A, Villela RA, Antonini SR, Elias PC, Martinelli CE, Jr., Castro M, Moreira AC, Paula FJ. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist. Clinics (Sao Paulo) 2012; 67:591-596
49. Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007; 92:2087-2099
50. Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L, Antoniazzi F, Tato L. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 2010; 93:1185-1191
51. Styne DM, Grumbach MM. Puberty: Ontogeny, neuroendocrinology, physiology and disorders. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. William's Textbook of Endocrinology, 12th ed. Philadelphia, PA: Elsevier-Saunders, 2011:1054-1201
52. Lewis KA, Eugster EA. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J Pediatr 2013; 162:562-565
53. Neely EK, Silverman LA, Geffner ME, Danoff TM, Gould E, Thornton PS. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol 2013; 2013:20
54. Hirsch HJ, Lahlou N, Gillis D, Strich D, Rosenberg-Hagen B, Chertin B, Farkas A, Hartman H, Spitz IM. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. J Clin Endocrinol Metab 2010; 95:2841-2844
55. Silverman LA, Kletter GB, Neely EK, Potts S, Gould E, Terleckyj O, Danoff TM. Recovery of normal hypothalamic pituitary gonadal function after treatment with subcutaneous histrelin implant for central precocious puberty. Endocrine Society's 94th Annual Meeting and Expo; June 24, 2012; Houston, Texas
56. Bertelloni S, Baroncelli GI. Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother 2013; 14:1627-1639